Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + PD-1 Inhibitor in Advanced/Metastatic Non-Squamous NSCLC
NCT06772623Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 17
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in non-small cell lung carcinoma (NSCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicities at 84 days, Objective Response at 33 months and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT06772623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772623.